Delpharm, a CDMO, has expanded its pharmaceutical development services with the acquisition of the Leiden Development Center from Dr Reddy’s in the Netherlands. This center employs forty highly qualified personnel and is located in a 3,500 square meter unit equipped with state-of-the-art technologies to develop injectable formulation for small and large molecules and to manufacture small batches for clinical trials.   With the acquisition of the Leiden site, Delpharm has expanded its sca...